Perryville Family Dentistry, Llc | |
75 Frontage Rd Asbury NJ 08802-1367 | |
(908) 730-8988 | |
Not Available |
Full Name | Perryville Family Dentistry, Llc |
---|---|
Speciality | Dentist - General Practice |
Location | 75 Frontage Rd, Asbury, New Jersey |
Authorized Official Name and Position | William A Townsend (D.D.S.) |
Authorized Official Contact | 9087308988 |
Accepts Medicare Insurance | This clinic does not participate in Medicare Program. |
Mailing Address | Practice Location Address |
---|---|
Perryville Family Dentistry, Llc 75 Frontage Rd Asbury NJ 08802-1367 Ph: () - | Perryville Family Dentistry, Llc 75 Frontage Rd Asbury NJ 08802-1367 Ph: (908) 730-8988 |
NPI Number | 1386826535 |
---|---|
Provider Enumeration Date | 11/29/2007 |
Last Update Date | 11/29/2007 |
Identifier | Type | State | Issuer |
---|---|---|---|
1386826535 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
1223G0001X | Dentist - General Practice | (* (Not Available)) | Primary |
News Archive
Recently, a drug named Pixantrone (PIX) was developed, which is far less damaging to the heart than previous, less advanced compounds. PIX is now used to treat cancers including non-Hodgkin's lymphoma and leukaemia, but a detailed knowledge of the molecular processes it uses to destroy cancer cells has been lacking so far.
Researchers at Erasmus MC University Medical Centre in The Netherlands found that cyclosporine treatment is a significant risk factor for the development of de novo cancer in liver transplant patients. Full details appear in the July issue of Liver Transplantation, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases.
A new enzyme originally developed for commercial food processing turns out to also quickly and nearly-completely break down whole gluten molecules as well as the T cell stimulatory peptides that cause celiac disease, a digestive disease with no current effective treatment other than avoiding wheat, barley or rye products.
Moffitt Cancer Center and Proteacel LLC announced today that they have entered a licensing agreement under which Proteacel has acquired the exclusive rights to the POREā¢ technology for delivery of genes into cells.
› Verified 6 days ago